The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious response from the company. In a statement, the company says the FDA's ...

Vanda is a high-frequency positioning data and tactical macro insights provider Vanda was FPE’s sixth investment from FPE Fund III Exante Data is based in New York FPE portfolio company Vanda has ...

Vanda said the FDA approved NEREUS (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. The approval marks the first new pharmacologic ...

FDA requests, and Vanda agrees to, a brief extension (to December 5, 2025) for the expedited re-review of the partial clinical hold on long-term studies Separately, FDA recently issued labeling ...

Vanda Pharmaceuticals stands at a pivotal point, leveraging strong Fanapt growth and a robust late-stage pipeline for future expansion. VNDA's aggressive investment in commercial infrastructure has ...

The New York Islanders today announced a multi-year agreement with Vanda Pharmaceuticals, a global biopharmaceutical company, naming them the team’s exclusive jersey patch partner. This landmark ...

Vanda and FDA's agreement includes expedited re-reviews of Tradipitant and Hetlioz applications, with target action dates in late 2025 and early 2026. The collaborative framework involves pausing ...

With a win in a D.C. appeals court, Vanda Pharmaceuticals has earned a point over the FDA in the yearslong face-off between the drugmaker and the drug regulator. Vanda has been fighting to market its ...

Vanda submitted its supplemental New Drug Application (sNDA) in October 2018 to market HETLIOZ ® to treat jet lag disorder. After the FDA substantially delayed resolving Vanda's request for a hearing ...

Vanda Pharmaceuticals won a legal battle as a federal court overturned the FDA's rejection of Hetlioz for jet lag disorder, highlighting the court's support for Vanda's evidence. The court criticized ...